Rami Fayed's lobbying: the registrations they file and every meeting they've reported since November 2021.
← LobbyingRegistrant (responsible officer)
Vice President and General Manager, Canada
For companies and organizations, the most senior paid officer files the registration and the monthly reports, whoever attended the meeting.
No registration in effect right now.
The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.
Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.
Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.
Communication regarding free trade agreements as they relate to the biopharmaceutical industry.
Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.
Innovation, Science and Economic Development (ISED)'s Health Emergency Readiness program, insofar as it pertains to growth and development of the life sciences industry in Canada.
Communications regarding intellectual property protection of prescription drugs, including the Patent Act, the Patented Medicines Regulations, the Patented Medicine Notice of Compliance (PMNOC) Regulations, the Patent Term Adjustment regime and Health Canada’s Data Protection regime.
Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.
Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.
Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.
The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.
Communication regarding free trade agreements as they relate to the biopharmaceutical industry.
Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.
Communication regarding free trade agreements as they relate to the biopharmaceutical industry.
Communications with Health Canada regarding modernization of clinical trials regulations, including diversity and inclusivity of clinical trials.
Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.
Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.
Communication regarding free trade agreements as they relate to the biopharmaceutical industry.
Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.
Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.
The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.
Communication regarding free trade agreements as they relate to the biopharmaceutical industry.
Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.
The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.
Communication regarding free trade agreements as they relate to the biopharmaceutical industry.
Innovation, Science and Economic Development (ISED)'s Biomanufacturing and Life Sciences Strategy, pertaining to growth and development of the life sciences industry in Canada.
The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.
Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.
Communications regarding access to and approval of medicines addressing the growing public health threat of antimicrobial resistance.
Communications regarding national pharmacare legislation, regulations, policies or programs.
Innovation, Science and Economic Development (ISED)'s Biomanufacturing and Life Sciences Strategy, pertaining to growth and development of the life sciences industry in Canada.
The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.
Communication regarding free trade agreements as they relate to the biopharmaceutical industry.
Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.
Communications regarding national pharmacare legislation, regulations, policies or programs.
Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.
Communications regarding national pharmacare legislation, regulations, policies or programs.
Communications regarding national pharmacare legislation, regulations, policies or programs.
Communications regarding national pharmacare legislation, regulations, policies or programs.
Innovation, Science and Economic Development (ISED)'s Biomanufacturing and Life Sciences Strategy, pertaining to growth and development of the life sciences industry in Canada.
Innovation, Science and Economic Development (ISED)'s Biomanufacturing and Life Sciences Strategy, pertaining to growth and development of the life sciences industry in Canada.
HealthIndustry
HealthIndustry
Health
Economic DevelopmentResearch and Development
Economic DevelopmentResearch and Development
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.